Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure

NCT02983071 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT02983071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2017
Completion date
October 31, 2023
Enrollment
102 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasm, carcinoma, ductal, breast